Retirement Planning Co of New England Inc. Increases Position in The Clorox Company (NYSE:CLX)

Retirement Planning Co of New England Inc. lifted its stake in The Clorox Company (NYSE:CLX - Free Report) by 138.3% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 11,070 shares of the company's stock after purchasing an additional 6,425 shares during the quarter. Retirement Planning Co of New England Inc.'s holdings in Clorox were worth $1,630,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of CLX. Natixis Advisors LLC raised its position in shares of Clorox by 6.0% in the 4th quarter. Natixis Advisors LLC now owns 67,296 shares of the company's stock valued at $10,930,000 after purchasing an additional 3,820 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its position in Clorox by 17.7% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 25,755 shares of the company's stock worth $4,183,000 after buying an additional 3,873 shares during the last quarter. Corient Private Wealth LLC raised its position in Clorox by 0.4% during the 4th quarter. Corient Private Wealth LLC now owns 28,652 shares of the company's stock worth $4,653,000 after buying an additional 117 shares during the last quarter. Cibc World Markets Corp raised its position in Clorox by 15.0% during the 4th quarter. Cibc World Markets Corp now owns 48,572 shares of the company's stock worth $7,889,000 after buying an additional 6,345 shares during the last quarter. Finally, Parallel Advisors LLC raised its position in Clorox by 11.1% during the 4th quarter. Parallel Advisors LLC now owns 5,006 shares of the company's stock worth $813,000 after buying an additional 500 shares during the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Clorox news, Director Pierre R. Breber acquired 4,000 shares of the company's stock in a transaction that occurred on Wednesday, May 7th. The stock was bought at an average price of $136.57 per share, with a total value of $546,280.00. Following the purchase, the director owned 4,000 shares in the company, valued at approximately $546,280. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.57% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Morgan Stanley reduced their price target on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Barclays set a $119.00 price target on shares of Clorox and gave the stock an "underweight" rating in a research report on Tuesday. UBS Group reduced their price target on shares of Clorox from $150.00 to $134.00 and set a "neutral" rating for the company in a research report on Thursday. JPMorgan Chase & Co. decreased their target price on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a research note on Tuesday, May 6th. Finally, Jefferies Financial Group decreased their target price on shares of Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $145.17.

Clorox Price Performance

Shares of NYSE CLX traded down $0.98 during trading on Friday, hitting $128.28. The company had a trading volume of 1,662,271 shares, compared to its average volume of 1,424,843. The stock has a fifty day simple moving average of $127.49 and a two-hundred day simple moving average of $141.59. The Clorox Company has a fifty-two week low of $117.35 and a fifty-two week high of $171.37. The firm has a market capitalization of $15.81 billion, a price-to-earnings ratio of 23.03, a price-to-earnings-growth ratio of 3.14 and a beta of 0.51. The company has a quick ratio of 0.44, a current ratio of 0.74 and a debt-to-equity ratio of 13.07.

Clorox (NYSE:CLX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a net margin of 9.89% and a return on equity of 324.23%. The company had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. During the same quarter last year, the business earned $1.71 EPS. The firm's revenue for the quarter was down 8.0% compared to the same quarter last year. On average, research analysts expect that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.